Literature DB >> 19383334

Innovations, challenges and future prospects of oncoproteomics.

Kewal K Jain1.   

Abstract

Oncoproteomics is playing an increasingly important role in the diagnosis and management of cancer as well as in the development of personalized treatment of cancer. Innovative proteomic technologies relevant to cancer are described briefly, which are helping in the understanding of mechanism of drug resistance in cancer and will provide some leads to improve the management. Most important of these are nanoproteomics, i.e. application of nanobiotechnology to proteomics is playing an important role in nanooncology. Examples of some cancers will be given to point out the challenges and future prospects of oncoproteomics including those involving translation of technologies from the bench to the bedside.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19383334      PMCID: PMC5527761          DOI: 10.1016/j.molonc.2008.05.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  31 in total

Review 1.  Molecular biologic staging of lung cancer.

Authors:  Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

Review 2.  Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.

Authors:  Shen Hu; Yun Yen; David Ann; David T Wong
Journal:  Drug Discov Today       Date:  2007-10-17       Impact factor: 7.851

3.  The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.

Authors:  Walter Schippinger; Nadia Dandachi; Peter Regitnig; Günter Hofmann; Marija Balic; Rainer Neumann; Hellmut Samonigg; Thomas Bauernhofer
Journal:  Am J Clin Pathol       Date:  2007-10       Impact factor: 2.493

Review 4.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

5.  Panel of serum biomarkers for the diagnosis of lung cancer.

Authors:  Edward F Patz; Michael J Campa; Elizabeth B Gottlin; Irina Kusmartseva; Xiang Rong Guan; James E Herndon
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

6.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells.

Authors:  Dihua Shangguan; Zehui Cao; Ling Meng; Prabodhika Mallikaratchy; Kwame Sefah; Hui Wang; Ying Li; Weihong Tan
Journal:  J Proteome Res       Date:  2008-03-26       Impact factor: 4.466

7.  Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.

Authors:  Primoz Drev; Snjezana Frković Grazio; Matej Bracko
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-03

8.  Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.

Authors:  Chary López-Pedrera; José Manuel Villalba; Emilio Siendones; Nuria Barbarroja; Consuelo Gómez-Díaz; Antonio Rodríguez-Ariza; Paula Buendía; Antonio Torres; Francisco Velasco
Journal:  Proteomics       Date:  2006-04       Impact factor: 3.984

Review 9.  Antibody arrays--an emerging tool in cancer proteomics.

Authors:  Eliezer Kopf; Dorit Zharhary
Journal:  Int J Biochem Cell Biol       Date:  2007-05-13       Impact factor: 5.085

Review 10.  Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening.

Authors:  Dean H Conrad; Jesse Goyette; Paul S Thomas
Journal:  J Gen Intern Med       Date:  2008-01       Impact factor: 5.128

View more
  9 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

Review 2.  Review on early technology assessments of nanotechnologies in oncology.

Authors:  Valesca P Retèl; Marjan J M Hummel; Wim H van Harten
Journal:  Mol Oncol       Date:  2009-05-20       Impact factor: 6.603

3.  The proteome of normal pancreatic juice.

Authors:  Courtney J Doyle; Kyle Yancey; Henry A Pitt; Mu Wang; Kerry Bemis; Michele T Yip-Schneider; Stuart T Sherman; Keith D Lillemoe; Michael D Goggins; C Max Schmidt
Journal:  Pancreas       Date:  2012-03       Impact factor: 3.327

Review 4.  Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology.

Authors:  George S Karagiannis; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-09-16       Impact factor: 6.603

5.  Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.

Authors:  Natini Jinawath; Chanont Vasoontara; Artit Jinawath; Xueping Fang; Kejia Zhao; Kai-Lee Yap; Tong Guo; Cheng S Lee; Weijie Wang; Brian M Balgley; Ben Davidson; Tian-Li Wang; Ie-Ming Shih
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

6.  A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Authors:  Pavel Gromov; Julio E Celis; Irina Gromova; Fritz Rank; Vera Timmermans-Wielenga; José M A Moreira
Journal:  Mol Oncol       Date:  2008-10-02       Impact factor: 6.603

Review 7.  Innovations, challenges and future prospects of oncoproteomics.

Authors:  Kewal K Jain
Journal:  Mol Oncol       Date:  2008-05-28       Impact factor: 6.603

8.  Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

Authors:  José M A Moreira; Gita Ohlsson; Pavel Gromov; Ronald Simon; Guido Sauter; Julio E Celis; Irina Gromova
Journal:  Mol Cell Proteomics       Date:  2009-09-25       Impact factor: 5.911

9.  Immunoexpression analysis and prognostic value of BLCAP in breast cancer.

Authors:  Irina Gromova; Pavel Gromov; Niels Kroman; Vera Timmermans Wielenga; Ronald Simon; Guido Sauter; José M A Moreira
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.